ENDRA Life Sciences (NASDAQ:NDRA) Share Price Crosses Below 200 Day Moving Average – Should You Sell?

ENDRA Life Sciences Inc. (NASDAQ:NDRA) shares passed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $4.80 and traded as low as $4.58. ENDRA Life Sciences shares last traded at $4.74, with a volume of 10,271 shares trading hands.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of ENDRA Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, October 14th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $25.00.

ENDRA Life Sciences Stock Performance

The business’s 50 day simple moving average is $5.43 and its 200 day simple moving average is $4.80.

ENDRA Life Sciences (NASDAQ:NDRA) last posted its earnings results on Friday, August 14th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.21. On average, equities analysts expect that ENDRA Life Sciences Inc. will post -4.11 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in ENDRA Life Sciences stock. Citizens Financial Group Inc. RI bought a new position in shares of ENDRA Life Sciences Inc. (NASDAQ:NDRA) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 28,400 shares of the company’s stock, valued at approximately $151,000. Citizens Financial Group Inc. RI owned approximately 2.24% of ENDRA Life Sciences at the end of the most recent quarter. Hedge funds and other institutional investors own 1.19% of the company’s stock.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company developing noninvasive diagnostic tools for tissue characterization. The company’s lead technology is Thermo-Acoustic Enhanced Ultrasound (TAEUS), which is designed to enhance conventional ultrasound systems with additional information about tissue properties.

ENDRA is initially applying TAEUS to the assessment of liver disease, including the detection and measurement of liver fat associated with conditions such as nonalcoholic fatty liver disease.